IDXXIdexx Laboratories
$675.90+7.5% 1Y
$675.90
$504.5952 weeks$766.68
What has happened
IDXX in its own filings
Nothing in IDXX's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
392
Events found in the filings · across 2,169 filings · the record starts in 1996
- Hard flags
- none
Hard flags
- Most recent filing
- Nov 2, 2026
Most recent filing · Form 8-K
- Record starts
- May 9, 1996
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Feb 1, 2027
- SEC comment-letter activity31 occurrences
- 2025-07-07
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Charter/bylaw amendment or fiscal-year change
Certificate of Incorporation At the 2026 annual meeting of shareholders of IDEXX Laboratories, Inc. (the “Corporation”) held on May 12, 2026 (the “Annual Meeting”), upon the recommendation of the Corporation’s Board of Directors (the “Board”), the Corporation’s shareholders approved amendments to the Corporation’s …
Form 8-K on sec.gov ↗
Earlier reports (7)›
- Director or officer change
On March 24, 2026, IDEXX Laboratories, Inc. (“IDEXX”) and Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, mutually agreed that Dr. Hunt will cease serving in her current role effective on April 13, 2026 (the “Separation Date”) and will continue to provide advisory services on an as-needed …
Form 8-K on sec.gov ↗ - Director or officer change
On February 13, 2026, Ms. M. Anne Szostak provided IDEXX Laboratories, Inc. (the “Company”) notice of her intention to retire from the Board of Directors (the “Board”) effective immediately following the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) to be held on May 12, 2026.
Form 8-K on sec.gov ↗ - Director or officer change
On January 11, 2026, Jonathan (Jay) Mazelsky notified IDEXX Laboratories, Inc. (the “Company” or “IDEXX”) of his intent to step down as the Company’s President and Chief Executive Officer effective as of May 12, 2026 (the “Transition Date”) and retire from the Company and the Company’s Board of the Directors (the …
Form 8-K on sec.gov ↗ - Material agreement entered
Amendment No. 2 to Fourth Amended and Restated Credit Agreement On November 12, 2025, IDEXX Laboratories, Inc. (the “Company”), with IDEXX Distribution, Inc., IDEXX Operations, Inc., OPTI Medical Systems, Inc., IDEXX Laboratories Canada Corporation, IDEXX B.V., IDEXX Laboratories B.V., IDEXX Laboratories GmbH, and …
Form 8-K on sec.gov ↗ - Director or officer change
Effective October 6, 2025, the board of directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”) elected Karen Peacock as an independent Class I Director and appointed her as a member of its Compensation and Talent Committee and Finance Committee.
Form 8-K on sec.gov ↗
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Diagnostics & Research
The closest names by size in the same industry